Best Treatment for Acne

Cystic Acne News

NANOBIO: Pharmaceutical firm attracts investments and partnershipsSunday, January 10, 2010 @ 3:28AMAn Ann Arbor-based biopharmaceutical company continues to attract investments, grants and partners, including a new licensing agreement with a large drug company to help it develop and sell the most advanced product in its pipeline.

Novel Intranasal Nanoemulsion Vaccine Adjuvant Also Effective by Subcutaneous and Intramuscular InjectionWednesday, December 2, 2009 @ 9:56AMANN ARBOR, Mich.----NanoBio Corporation today announced positive results from studies in mice in which immune responses were evaluated following administration of 5µg doses of recombinant H5N1 pandemic flu antigen combined with the company’s novel nanoemulsion vaccine.

NuU Medspa Help Raise Awareness for Attack ACC Foundation, September 12, 2009Tuesday, September 22, 2009 @ 3:05AMNuU Medspa joined the Attack ACC Foundation for their Third Annual 5 Mile Family Run/Walk on September 12, 2009 at 9:00 a.m. at Hickory Creek Junction (Rt. 30 Lincoln Highway - 1 mile west of Wolf Rd.). NuU Medspa donates their efforts and empathy to Attack ACC (Adenoid Cystic Carcinoma) Foundation, a rare cancer that lacks research for a cure. Attack ACC is a serious but rare cancer that falls ...

Morria Biopharmaceuticals Plc. Obtains Institutional Review Board Clearance To Conduct Phase II Study In Contact ...Wednesday, August 26, 2009 @ 12:18PMMorria Biopharmaceuticals Plc, a biopharmaceutical company focusing on novel, non-steroidal anti-inflammatory drugs, announced that it has received written approval to commence its Phase II clinical trial on its leading topical Multi-Functional Anti Inflammatory Drug (MFAID) MRX6.

NanoBio to Present Preclinical Data on its Novel, Nanoemulsion-based Vaccine Adjuvant Platform at the ...Monday, August 17, 2009 @ 2:15PMANN ARBOR, Mich.----NanoBio Corp. announced today that it is giving an oral presentation at the 2009 Immunotherapeutics & Vaccine Summit, which will include preclinical data demonstrating that its intranasal nanoemulsion adjuvant technology significantly enhances the immune response to influenza vaccines.